Corticosteroid Treatment For Preterm Babies May Cause Mental and Behavioral Disorders: Study

Giving corticosteroids to pregnant women may help save an infant’s life, but the side effects may also increase the child’s risk of suffering mental health disorders later, according to the findings of new research.

In a study published this month in the Journal of the American Medical Association (JAMA), researchers from Finland and Sweden found that children exposed to maternal corticosteroids had an increased risk of developing both mental and behavioral disorders compared to children whose mothers did not receive the treatment.

Researchers conducted a population-based retrospective cohort study including more than 670,000 children. They used data from nationwide registries of single births in Finland and compared children with sibling pregnancies born full term. Children included in the study were born between 2006 and 2017.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

Overall, nearly 15,000 children were exposed to corticosteroid treatment. Among those, roughly 45% were born at term and 54% were born preterm, or before 34 weeks of pregnancy. They were compared to more than 655,000 non-exposed children. More than 96% of them were born at term while 3% were preterm.

Among all children, those who had maternal exposure to the corticosteroid had a 12% increased risk of developing any mental or behavioral disorder. Children who did not have exposure to the corticosteroid had a 6% increased risk.

Children born at term and exposed had an 8% increased risk of mental or behavioral disorders later in childhood. Siblings who were exposed to treatment had a 6.5% increased risk of developing a mental or behavioral disorder compared to their siblings who were not exposed.

Exposure to maternal antenatal corticosteroid treatment was significantly associated with mental and behavioral disorders in children.

Maternal antenatal corticosteroid treatment is standard care to accelerate fetal maturation when a baby will be born before 34 weeks. Maternal corticosteroid treatment can be lifesaving for infants born extremely preterm. It is often given to help prevent respiratory distress and help a baby born early survive the crucial first weeks. However, the long-term effects are largely unknown.

Corticosteroids are a type of drug that can cross the placenta and cross the blood-brain barrier. This means they can have a profound effect on the infant’s development.

“In this population-based cohort study, exposure to maternal antenatal corticosteroid treatment was significantly associated with mental and behavioral disorders in children,” wrote study authors. “These findings may help inform decisions about maternal antenatal corticosteroid treatment.”

1 Comments

  • JessicaFebruary 24, 2022 at 10:05 pm

    I would not have gotten this treatment if i would have been informed of the risks

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL
Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL (Posted yesterday)

The U.S. District Judge presiding over all Suboxone lawsuits has created a mentorship program to use the litigation to provide some attorneys an opportunity to gain experience in handling complex federal multidistrict litigations.

Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M
Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M (Posted 3 days ago)

Gilead says it will pay $40 million to resolve HIV drug lawsuits over Truvada, Atripla, Viread, Stribild and Complera pending in the federal court system, involving claims that the the company sat on safer formulations of the drugs for years to increase profits.